Publicacións en colaboración con investigadores/as de Institute Catalá Oncología (10)

2024

  1. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

2023

  1. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study

    Melanoma research, Vol. 33, Núm. 5, pp. 388-397

  2. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

  3. Treatment variability and its relationships to outcomes among patients with Wernicke's encephalopathy: A multicenter retrospective study

    Drug and Alcohol Dependence, Vol. 252

2022

  1. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

2021

  1. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    Therapeutic Advances in Medical Oncology, Vol. 13

  2. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

    Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456

  3. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry

    Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936

2020

  1. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

    PloS one, Vol. 15, Núm. 7, pp. e0235848

2015

  1. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program

    American Journal of Hematology, Vol. 90, Núm. 5, pp. 429-433